MPM BioVentures 2014, L.P. sold $296k of HOWL
owner at Werewolf Therapeutics, Inc.. 242,890 shares at an average of $1.22, traded Nov 4, 2025, filed Nov 6, 2025.
Score components
- +12Role10% owner
- +14Trade size$296k at market
- 0Share of holdings soldSold 4.0% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-25-000441, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 4, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -140,488 | $1.22 | $171k | 6,007,122 | Nov 6, 2025 |
| Nov 5, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -47,950 | $1.22 | $58k | 5,959,172 | Nov 6, 2025 |
| Nov 6, 2025 | SOpen-market sale Common Stockindirect: See Footnote10b5-1 | -54,452 | $1.21 | $66k | 5,904,720 | Nov 6, 2025 |
Related signals
Other insiders at Werewolf Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $21k 38,782 shares | -2% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $62k 111,227 shares | -5% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $54k 91,374 shares | -4% | |
| 1Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $46k 71,054 shares | -3% | |
| 2Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $48k 78,377 shares | -3% | |
| 12Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $185k 291,283 shares | -10% | |
| 17Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $52k 48,171 shares | -2% | |
| 19Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $89k 82,971 shares | -3% | |
| 20Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $95k 95,179 shares | -3% | |
| 20Weak | Werewolf Therapeutics, Inc. | Luke Evnin director | $118k 128,185 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.